CAMBRIDGE, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today the pricing of its previously announced underwritten public offering of 3,950,000 of its ordinary shares at a price to the public of $38.00 per ordinary share. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 592,500 of its ordinary shares on the same terms and conditions. The offering is expected to close on or about January 28, 2019, subject to customary closing conditions.

Jefferies, SVB Leerink and Mizuho Securities are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey and H.C. Wainwright & Co. are acting as co-managers.

About Wave Life Sciences

Wave Life Sciences is a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Its chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. The company’s pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.